20251106-太平洋-金河生物-002688.SZ-2025年三季报点评_化药持续发力_新兴业务打开长期空间_5页_675kb

Jinhe Bio (002688) 2025 Q3 Report Summary

Key Financial Performance

Jinhe Bio reported Q3 2025 with a significant decline in quarter-on-quarter net profit, primarily due to seasonality, facility maintenance, and higher costs. However,前三季度 performance remained robust:

• Revenue increased by 22.86% year-over-year to 20.36 billion yuan.
• Net profit grew by 22.25% to 1.39 billion yuan, with Q3 showing a sharp drop to 1.15 million yuan, reflecting temporary setbacks.

Business Segments

The company's diversified portfolio mitigates risks:

• Chemical drugs (兽用化药) led growth, with revenue jumping 55.49% to 12.85 billion yuan and product sales volumes rising; cost reductions from lower raw material prices improved margins.
• Biological products faced competition pressures, with revenue down 4.15%, but key vaccines like "佑蓝宝" saw strong demand growth.
• Emerging areas include new vaccines and pet health products, with projected substantial expansion in Revenue.

Future Outlook

Jinhe Bio anticipates sustained growth driven by:

• 2026 price increases and expanded markets for antibiotics.
• New product launches and capacity expansions, contributing additional revenue streams.

Financial Projections

Pacific Securities projects:

• Revenue: 28.01 billion yuan (2025), 33.02 billion (2026), 39.24 billion (2027).
• Net profit: 1.84 billion (2025), 2.4 billion (2026), 3.33 billion (2027).
• PE ratios: 26.19 (2025), 20.06 (2026), 14.50 (2027).
• PE rating: Supports "买入" recommendation due to strong growth prospects.

Risk Factors

Potential risks include product price volatility, tariff uncertainties, market fluctuations, and input cost increases.